Technology startup offers personalized and print boutique-quality greeting cards
Card Isle was founded in 2013 by three Virginia Tech engineering students passionate about making greeting cards more personal, accessible and fun! www.cardisle.com
Card Isle www.cardisle.com
Richmond, VA, Oct. 12, 2020 (GLOBE NEWSWIRE) — The Center for Innovative Technology (CIT) today announced that the Virginia Founders Fund (VFF) has invested in Card Isle, a Blacksburg, Va.-based technology company that is rethinking how greeting cards can be distributed in a changing retail landscape. Card Isle offers turnkey solutions to design, order, and print personalized greeting cards, and will use this capital from VFF to continue their rapid growth in the eCommerce gifting sector and develop new markets.
Greeting cards have a unique ability to connect people
Linwei Wang has been named the new director of the Personalized Healthcare Technology signature research initiative at Rochester Institute of Technology. Adam Smith has been named creative director, a new position with the group. It is one of RIT’s strategic research areas and has been instrumental in the development of new health care solutions in areas such as non-invasive technologies, technology-based behavioral health, and new capabilities in cardiac care.
Wang will take on the role held by David Borkholder, who is taking leave from the university to serve as the head of research and development for the start-up company, Heart Health Intelligence (HHI).
Adam Smith, an associate professor in the School of Design, show here in a 2018 file photo, has been named creative director of the Personalized Healthcare Technology signature research initiative.
“Since the initiative began in 2016, we have seen exciting growth in healthcare research
Business models that rely on personalized advertising are “under assault” by iOS 14 privacy changes, Facebook’s chief revenue officer said Tuesday.
The changes include a new feature that requires users to opt-in to tracking via Identifier for Advertiser, or IDFA, tags on a per-app basis. Although initially planned for the general iOS 14 release, Apple delayed the rollout of the feature until 2021 following public outcry from a number of companies that gain a bulk of their revenue from ad serving, including Facebook.
Speaking digitally at Advertising Week on Tuesday, Facebook CFO David Fischer said that “the very tools that entrepreneurs, that businesses are relying on right now are being threatened,” CNBC reported.
“To me, the changes that Apple has proposed, pretty sweeping changes, are going to hurt developers and businesses the most,” Fischer added, singling out the IDFA change in iOS.
Already tested and loved by leading brands such as Sky TV, Journey offers the most cutting edge approach to content personalization. Using smart technology, Journey truly helps brands open up a dialogue with consumers, match them with the right product offerings in real-time while they are engaged and interested, and gain invaluable first-hand reported insights that can immediately be activated upon for comprehensive consumer profiles, audience segmentation and retargeting capabilities.
Sky TV partnered with EX.CO for a recent Netflix campaign in which they used the Journey feature to pair users with specific TV shows based on their respective responses to questions about their day. The content stood out to target audiences, resulting in an impressive Nielsen Brand Uplift score of 1120% vs. the average 10.2% for entertainment campaigns, a Click-Through-Rate of 9% (well above the industry recognized benchmark of 1%), and a Completion Rate of 84.3%. Sky and Netflix then
Patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy, report University of California San Diego School of Medicine researchers.
Led by Razelle Kurzrock, MD, director of the Center for Personalized Cancer Therapy at Moores Cancer Center and senior author of the study, a multidisciplinary molecular tumor board was established to advise treating physicians on course of care using an individual patient’s molecular tumor makeup to design precision medicine strategies.
“Patients who underwent a molecular tumor board-recommended therapy were better matched to genomic alterations in their cancer and had improved outcomes,” said Kurzrock. “The three-year survival for patients with the highest degree of matching and who received a personalized cancer therapy was approximately 55 percent compared to 25 percent in patients who received therapy that
“It is more important to know what kind of patient the disease has than to know what kind of disease the patient has.”
Although Hippocrates made this keen observation more than 2,400 years ago, physicians did not have the tools to decipher the biological and environmental factors influencing an individual’s health and well-being until recently.
Since the human genome was finally mapped in 2003, scientists have made tremendous progress in advancing personalized medicine. By tailoring health care to an individual’s biological characteristics, circumstances, and values, personalized medicine can bring unprecedented benefits to patients with rare genetic disorders, cancer, and other diseases.
The widely variable effects of the novel coronavirus serve as a painful reminder of the importance of understanding how and why people respond differently to the same disease.
But two recent moves by the Trump administration threaten to turn back the clock on biomedical progress in personalized
Singapore, 22 September 2020 – Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP), an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation (NRF) Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries. The grants are part of the NRF’s initiative to bring together researchers from Campus for Research Excellence And Technological Enterprise (CREATE) partner institutions, in order to achieve greater impact from collaborative research efforts.
SMART CAMP was formed in 2019 to focus on ways to produce living cells as medicine delivered to humans to treat a range of illnesses and medical conditions, including tissue degenerative diseases, cancer, and autoimmune disorders.
“Singapore’s well-established biopharmaceutical ecosystem brings with it a thriving research ecosystem that is supported by skilled talents and strong manufacturing